Plasma Copper and Zinc Levels in Ataxia-Telangiectasia

Area of Science:

• Neurogenetics
• Trace Element Metabolism
• Biomarker Discovery

Background:

• Ataxia-Telangiectasia (A-T) is a rare, inherited neurodegenerative disorder caused by ATM gene mutations.
• ATM protein influences cellular processes similar to copper and zinc, including oxidative stress and apoptosis.
• Imbalances in copper and zinc may contribute to A-T's clinical manifestations and cancer risk.

Purpose of the Study:

• To investigate plasma copper and zinc levels in individuals diagnosed with A-T.
• To explore the potential of copper and zinc as biomarkers for A-T disease progression.
• To assess if copper and zinc imbalances contribute to A-T pathogenesis.

Main Methods:

• Retrospective cohort study design.
• Analysis of plasma copper and zinc levels in 37 A-T patients.
• Comparison with age-related reference values and mixed-effects modeling for longitudinal changes.

Main Results:

• Pediatric A-T patients exhibited lower zinc levels compared to controls.
• Adult patients with classic A-T showed reduced copper levels, unlike those with variant A-T.
• Mixed model analysis revealed minimal longitudinal changes, suggesting limited utility as progression biomarkers.

Conclusions:

• Copper and zinc metabolism appear dysregulated in Ataxia-Telangiectasia.
• Copper and zinc levels do not serve as reliable biomarkers for monitoring A-T disease progression.
• Further research may explore therapeutic potential of modulating copper and zinc in A-T.